Subscribe
Strategy
3 min

Loyal taps Argenta for early development of its LOY-003 dog drug

Loyal has brought in animal health contract manufacturer Argenta to support early-stage development of LOY-003, its daily pill for large and giant-breed dogs.

Written by
The Underbite
Published on
November 17, 2026
Loyal taps Argenta for early development of its LOY-003 dog drug

Loyal has brought in Argenta, a contract research, development and manufacturing company that describes itself as dedicated exclusively to animal health, to support early-stage development of LOY-003. LOY-003 is Loyal's daily pill for large and giant-breed dogs, and the two companies call the deal a strategic partnership with the potential to expand as the program advances.

LOY-003 works by regulating growth hormone and IGF-1, two hormones Loyal ties to adult size and shortened lifespan in big dogs. Loyal's product page lists it for dogs 5 years and older that weigh at least 60 lb, prescribed by a veterinarian. Loyal said in September that the FDA had accepted LOY-003's reasonable expectation of effectiveness, the efficacy bar for conditional approval, which we covered in our report on that milestone.

Loyal founder and CEO Celine Halioua said, "Argenta's focus on animal health and their integrated capabilities make them a strong partner as we begin early-stage development of LOY-003."

Argenta CEO Matt Stober said, "Pioneering programs like LOY-003 are exactly what our Molecule to Market model is built to support." Argenta describes that model as formulation and process development, analytical and regulatory support, clinical trial supply and commercial manufacturing under one roof, according to its announcement.

Argenta's reach runs from formulation to commercial supply

Argenta was founded in 2006, and its site puts its team at more than 1,000 scientists, veterinarians, engineers and consultants. It lists three GMP manufacturing sites in Shawnee, Kansas, Auckland, New Zealand, and Dundee, Scotland, with about 665,000 ft² of production space between them. It says it has manufactured more than 125 commercial products and supplies more than 50 countries.

The Shawnee site, which Argenta calls its primary U.S. development and manufacturing hub, makes sterile injectables and oral solid doses including tablets and soft chews, and it houses a pilot plant. Argenta said it is investing in that facility.

Loyal says it has raised more than $250M and has three drugs in development, including through the $100M Series C round we reported in February. LOY-001, the other large-breed program, is a veterinarian-administered long-acting product given a few times a year to dogs 7 and older that weigh at least 40 lb, according to Loyal's product page. Its lead drug, LOY-002 for senior dogs, is the subject of the STAY trial, which Loyal's site puts at 1,317 dogs across 70 veterinary practices.

Other canine aging programs are testing different approaches

The Dog Aging Project is running TRIAD, a double-blind, placebo-controlled trial of rapamycin in dogs 7 and older that weigh 44 to 120 lb, funded by a 2024 National Institutes of Health grant and donations. Owners give the study drug weekly and visit a trial site every six months for three years, according to the project.

Genflow Biosciences, a London-listed gene therapy company, reported preliminary interim results in February from a 24-beagle study of its SIRT6 gene therapy, and it said it is engaging with animal health companies about licensing and co-development. On the manufacturing side, Aenova Group also lists animal health contract development and manufacturing, including companion-animal dosage forms for pain, dermatology and infections.

LOY-003 still has regulatory steps ahead

Conditional approval differs from full approval in the effectiveness standard, according to the FDA. A company must show a reasonable expectation of effectiveness rather than the substantial evidence that full approval requires, and the approval runs for one year, renewable up to four more times for a maximum of five years. Loyal's site says LOY-002 has completed two of the three major requirements for conditional approval, with manufacturing still in progress.

For veterinary practices, the relevant point is the prescriber role. Loyal's site describes LOY-003 as a pill prescribed by a veterinarian, and the company runs a free library of RACE-approved continuing education courses on canine aging for veterinary teams. For contract manufacturers and rival developers, the announcement shows Loyal lining up development help for LOY-003 from a specialist animal health provider.

Loyal says it is making progress toward FDA approval, and the Argenta collaboration starts with early development of one of its three drugs.

Source: Argenta and Loyal via Business Wire

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
CompanAIn names animal health veteran Brük Herbst COO
People
4 min read

CompanAIn names animal health veteran Brük Herbst COO

CompanAIn, a Charleston company building an AI-native health platform for dogs, cats and horses, named Brük Herbst chief operating officer. Herbst, a former IDEXX, Covetrus and Zomedica executive, will lead its move from platform validation to commercial scale.

Read article
Read article
Pivotal Group buys animal health manufacturer Precision Science
Funding & M&A
3 min read

Pivotal Group buys animal health manufacturer Precision Science

Pivotal Group, a Phoenix investment firm, has acquired Precision Science, a Phoenix animal health contract manufacturer founded in 1989. Pivotal said a 130,000-square-foot North Phoenix plant, two-thirds complete, will add three manufacturing lines and expand into liquids.

Read article
Read article
Vetoquinol wins FDA approval for Felpreva, a quarterly cat treatment
Regulatory
3 min read

Vetoquinol wins FDA approval for Felpreva, a quarterly cat treatment

Vetoquinol won FDA approval for Felpreva, a prescription topical parasiticide for cats applied four times a year, with vets able to order in 2027.

Read article
View all articles